WO2016012632A9 - Sales de tungsteno (vi) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida - Google Patents

Sales de tungsteno (vi) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida Download PDF

Info

Publication number
WO2016012632A9
WO2016012632A9 PCT/ES2014/070586 ES2014070586W WO2016012632A9 WO 2016012632 A9 WO2016012632 A9 WO 2016012632A9 ES 2014070586 W ES2014070586 W ES 2014070586W WO 2016012632 A9 WO2016012632 A9 WO 2016012632A9
Authority
WO
WIPO (PCT)
Prior art keywords
tungsten
effectiveness
female mammal
improving
salts used
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ES2014/070586
Other languages
English (en)
French (fr)
Other versions
WO2016012632A1 (es
Inventor
Ignacio CANALS ALMAZÁN
Agnès ARBAT BUGIÉ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxolife SL
Original Assignee
Oxolife SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HUE14898173A priority Critical patent/HUE061726T2/hu
Priority to EP14898173.1A priority patent/EP3173382B1/en
Priority to PL14898173.1T priority patent/PL3173382T3/pl
Priority to PCT/ES2014/070586 priority patent/WO2016012632A1/es
Priority to HRP20230223TT priority patent/HRP20230223T1/hr
Priority to PT148981731T priority patent/PT3173382T/pt
Priority to RS20230179A priority patent/RS64025B1/sr
Priority to KR1020177004653A priority patent/KR102282865B1/ko
Priority to JP2017502966A priority patent/JP6534439B2/ja
Priority to SG11201700485VA priority patent/SG11201700485VA/en
Priority to SI201432020T priority patent/SI3173382T1/sl
Priority to LTEPPCT/ES2014/070586T priority patent/LT3173382T/lt
Priority to CN201480082106.9A priority patent/CN106715332B/zh
Priority to MX2017000927A priority patent/MX383705B/es
Priority to RU2017105257A priority patent/RU2679623C2/ru
Priority to BR112017001287-1A priority patent/BR112017001287A2/pt
Priority to DK14898173.1T priority patent/DK3173382T3/da
Application filed by Oxolife SL filed Critical Oxolife SL
Priority to US15/327,292 priority patent/US10376540B2/en
Priority to FIEP14898173.1T priority patent/FI3173382T3/fi
Priority to SM20230086T priority patent/SMT202300086T1/it
Priority to NZ728467A priority patent/NZ728467B2/en
Priority to AU2014401750A priority patent/AU2014401750B2/en
Priority to CA2955914A priority patent/CA2955914C/en
Priority to ES14898173T priority patent/ES2940465T3/es
Priority to ARP150102288A priority patent/AR101252A1/es
Priority to UY0001036222A priority patent/UY36222A/es
Priority to TW104123580A priority patent/TWI709407B/zh
Publication of WO2016012632A1 publication Critical patent/WO2016012632A1/es
Anticipated expiration legal-status Critical
Priority to IL250212A priority patent/IL250212B/en
Priority to ZA2017/01241A priority patent/ZA201701241B/en
Publication of WO2016012632A9 publication Critical patent/WO2016012632A9/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G41/00—Compounds of tungsten
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G41/00—Compounds of tungsten
    • C01G41/02—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Powder Metallurgy (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)
  • Inorganic Insulating Materials (AREA)
  • Radiation-Therapy Devices (AREA)
  • Electroplating And Plating Baths Therefor (AREA)

Abstract

Sales de tungsteno (VI) para su uso en el tratamiento de la infertilidad en un mamífero hembra no diabético, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, o para aumentar la eficacia de una técnica de reproducción asistida aplicada a un mamífero, así como composiciones que las contienen y métodos de tratamiento con las mismas.
PCT/ES2014/070586 2014-07-21 2014-07-21 Sales de tungsteno (vi) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida Ceased WO2016012632A1 (es)

Priority Applications (29)

Application Number Priority Date Filing Date Title
DK14898173.1T DK3173382T3 (da) 2014-07-21 2014-07-21 Wolfram(vi)-salte til stimulering af fertilitet og reproduktion og til forbedring af effektiviteten af assisterede reproduktionsteknikker
PL14898173.1T PL3173382T3 (pl) 2014-07-21 2014-07-21 Sole wolframu(vi) do stymulowania płodności i reprodukcji oraz do poprawy skuteczności technik wspomaganego rozrodu
PCT/ES2014/070586 WO2016012632A1 (es) 2014-07-21 2014-07-21 Sales de tungsteno (vi) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida
HRP20230223TT HRP20230223T1 (hr) 2014-07-21 2014-07-21 Soli volframa (vi) za poticanje plodnosti i reprodukcije te za poboljšanje učinkovitosti tehnika potpomognute reprodukcije
PT148981731T PT3173382T (pt) 2014-07-21 2014-07-21 Sais de tungsténio (vi) utilizados para tratar infertilidade, para estimular a fertilidade e a reprodução normal num mamífero fêmea não diabético, e para melhorar a eficácia das técnicas de reprodução assistida
RS20230179A RS64025B1 (sr) 2014-07-21 2014-07-21 Soli volframa (vi) za stimulaciju plodnosti i reprodukcije i za poboljšanje efikasnosti tehnika potpomognute reprodukcije
KR1020177004653A KR102282865B1 (ko) 2014-07-21 2014-07-21 비당뇨병 암컷 포유류에서 불임 치료를 위해, 수정 및 정상 생식을 자극하기 위해, 및 보조 생식 기술의 효과를 개선하기 위해 사용되는 텅스텐(vi) 염
JP2017502966A JP6534439B2 (ja) 2014-07-21 2014-07-21 非糖尿病の雌性哺乳動物において生殖能力及び正常な妊孕力を刺激するための及び生殖補助医療の有効性を改善させるための、不妊症の治療に使用されるタングステン（ｖｉ）塩
SG11201700485VA SG11201700485VA (en) 2014-07-21 2014-07-21 Tungsten (vi) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques
US15/327,292 US10376540B2 (en) 2014-07-21 2014-07-21 Tungsten (VI) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques
LTEPPCT/ES2014/070586T LT3173382T (lt) 2014-07-21 2014-07-21 Volframo (vi) druskos, skirtos vaisingumui ir reprodukcijai skatinti bei pagalbinio apvaisinimo metodų veiksmingumui gerinti
CN201480082106.9A CN106715332B (zh) 2014-07-21 2014-07-21 用于治疗不孕症、促进雌性哺乳动物的正常繁殖和生育力及提高辅助生殖技术功效的钨盐
MX2017000927A MX383705B (es) 2014-07-21 2014-07-21 Sales de tungsteno (vi) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida.
RU2017105257A RU2679623C2 (ru) 2014-07-21 2014-07-21 Соли вольфрама (vi) для применения в лечении инфертильности, для поддержания нормальной репродуктивной функции и фертильности у недиабетической самки млекопитающего, а также для повышения эффективности вспомогательных репродуктивных технологий
BR112017001287-1A BR112017001287A2 (pt) 2014-07-21 2014-07-21 sal de tungstênio, composição, utilização de um sal de tungstênio e método para o tratamento da infertilidade
HUE14898173A HUE061726T2 (hu) 2014-07-21 2014-07-21 Wolfrám (VI) sók termékenység és reprodukció stimulálására és elõsegített reprodukciós technika hatékonyságának fokozására
EP14898173.1A EP3173382B1 (en) 2014-07-21 2014-07-21 Tungsten (vi) salts for stimulating fertility and reproduction and for improving the effectiveness of assisted reproduction techniques
SI201432020T SI3173382T1 (sl) 2014-07-21 2014-07-21 Volframove (VI) soli za stimuliranje plodnosti in reprodukcije ter za izboljšanje učinkovitosti tehnik asistirane reprodukcije
FIEP14898173.1T FI3173382T3 (fi) 2014-07-21 2014-07-21 Volframi(VI)suoloja hedelmällisyyden ja lisääntymiskyvyn stimuloimista ja keinohedelmöitystekniikoiden tehokkuuden parantamista varten
SM20230086T SMT202300086T1 (it) 2014-07-21 2014-07-21 Sali di tungsteno (vi) per stimolare la fertilità e la riproduzione e per migliorare l'efficacia di tecniche di riproduzione assistita
NZ728467A NZ728467B2 (en) 2014-07-21 Tungsten (vi) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques
AU2014401750A AU2014401750B2 (en) 2014-07-21 2014-07-21 Tungsten (VI) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques
CA2955914A CA2955914C (en) 2014-07-21 2014-07-21 Tungsten (vi) salts for use thereof in the treatment of infertility, for favoring normal reproduction and fertility in a non-diabetic female mammal, as well as for improving the efficacy of assisted reproductive techniques
ES14898173T ES2940465T3 (es) 2014-07-21 2014-07-21 Sales de tungsteno (VI) para estimular la fertilidad y la reproducción y para mejorar la eficacia de las técnicas de reproducción asistida
ARP150102288A AR101252A1 (es) 2014-07-21 2015-07-20 Sales de tungsteno (vi) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida
UY0001036222A UY36222A (es) 2014-07-21 2015-07-20 Sales de tungsteno (VI) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida.
TW104123580A TWI709407B (zh) 2014-07-21 2015-07-21 用於治療不孕症、有利於非糖尿病雌性哺乳類之正常生殖及生育力及促進輔助性生殖技術之功效之鎢（ｖｉ）鹽
IL250212A IL250212B (en) 2014-07-21 2017-01-22 Tungsten salts (vi) for use in the treatment of infertility, to favor normal fertility and reproduction in the female of non-diabetic mammals, as well as to improve the efficiency of assisted reproduction techniques
ZA2017/01241A ZA201701241B (en) 2014-07-21 2017-02-20 Tungsten (vi) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2014/070586 WO2016012632A1 (es) 2014-07-21 2014-07-21 Sales de tungsteno (vi) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida

Publications (2)

Publication Number Publication Date
WO2016012632A1 WO2016012632A1 (es) 2016-01-28
WO2016012632A9 true WO2016012632A9 (es) 2017-05-18

Family

ID=55162540

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2014/070586 Ceased WO2016012632A1 (es) 2014-07-21 2014-07-21 Sales de tungsteno (vi) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida

Country Status (28)

Country Link
US (1) US10376540B2 (es)
EP (1) EP3173382B1 (es)
JP (1) JP6534439B2 (es)
KR (1) KR102282865B1 (es)
CN (1) CN106715332B (es)
AR (1) AR101252A1 (es)
AU (1) AU2014401750B2 (es)
BR (1) BR112017001287A2 (es)
CA (1) CA2955914C (es)
DK (1) DK3173382T3 (es)
ES (1) ES2940465T3 (es)
FI (1) FI3173382T3 (es)
HR (1) HRP20230223T1 (es)
HU (1) HUE061726T2 (es)
IL (1) IL250212B (es)
LT (1) LT3173382T (es)
MX (1) MX383705B (es)
PL (1) PL3173382T3 (es)
PT (1) PT3173382T (es)
RS (1) RS64025B1 (es)
RU (1) RU2679623C2 (es)
SG (1) SG11201700485VA (es)
SI (1) SI3173382T1 (es)
SM (1) SMT202300086T1 (es)
TW (1) TWI709407B (es)
UY (1) UY36222A (es)
WO (1) WO2016012632A1 (es)
ZA (1) ZA201701241B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512535A (zh) 2018-05-29 2021-03-16 南澳弗林德斯大学 用于提高胚胎着床的方法
EP4368577A1 (en) 2022-11-08 2024-05-15 Oxolife, S.L. Process for the preparation of tungsten (vi) salt hydrates
WO2026008874A1 (en) 2024-07-05 2026-01-08 Oxolife, S.L. Tungsten (vi) salts for use for increasing ongoing pregnancies, for increasing live birth rates and/or for increasing the biochemical pregnancy rate in infertile women

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2245374B1 (es) * 1973-07-27 1977-02-25 Anvar
US4328134A (en) * 1980-05-06 1982-05-04 Schally Andrew Victor Anorexigenic peptides
ES2108642B1 (es) 1995-07-26 1998-08-16 Quimica Farm Bayer Sa Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.
RU2202314C2 (ru) * 2001-04-11 2003-04-20 Алексей Иванович Ступко Способ подготовки пациентки к искусственному оплодотворению
ES2187276B1 (es) * 2001-05-16 2004-08-01 Quimica Farmaceutica Bayer,S.A. Composiciones orales para el tratamiento de humanos obesos y no diabeticos.
WO2004030687A1 (en) * 2002-10-02 2004-04-15 Yeda Research And Development Co. Ltd. Long-acting gonadotropin-releasing hormone analogs and methods of use thereof
ES2342461T3 (es) * 2003-10-17 2010-07-07 Oy Neurofood Ab Agente de estroncio no radiactivo para tratar el cancer.
CN102989009B (zh) * 2003-12-31 2015-06-03 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
CA2642008A1 (en) * 2005-07-05 2007-01-11 Fertility Technologies Pty Ltd Methods and compositions for improving pregnancy outcome
US20080206356A1 (en) * 2005-07-29 2008-08-28 Universidad De Barcelona Pharmaceutical Compositions for the Treatment of Neurodegenerative Disorders
US20060100154A1 (en) * 2005-10-13 2006-05-11 Yeda Research And Development Co Long-acting gonadotropin-releasing hormone analogs and methods of use thereof
EP2416156B1 (en) * 2006-10-18 2015-12-30 Periness Ltd. Method for determining a male fertility status
ES2478790B1 (es) * 2013-01-22 2015-05-06 Oxolife, S. L. Uso de sales de tungsteno (VI) para el tratamiento de la infertilidad femenina en mamíferos no diabéticos
ES2551828B1 (es) * 2014-05-21 2016-09-12 Oxolife S.L. Composiciones alimentarias que comprenden sales de tungsteno (VI)

Also Published As

Publication number Publication date
AU2014401750B2 (en) 2019-10-24
AR101252A1 (es) 2016-12-07
KR102282865B1 (ko) 2021-07-28
TWI709407B (zh) 2020-11-11
WO2016012632A1 (es) 2016-01-28
ES2940465T3 (es) 2023-05-08
KR20170029627A (ko) 2017-03-15
CN106715332A (zh) 2017-05-24
FI3173382T3 (fi) 2023-03-25
CN106715332B (zh) 2019-01-29
RS64025B1 (sr) 2023-03-31
DK3173382T3 (da) 2023-03-13
IL250212A0 (en) 2017-03-30
SG11201700485VA (en) 2017-02-27
PT3173382T (pt) 2023-03-10
UY36222A (es) 2016-01-29
EP3173382B1 (en) 2023-01-04
US20170173074A1 (en) 2017-06-22
IL250212B (en) 2020-06-30
NZ728467A (en) 2021-04-30
RU2017105257A (ru) 2018-08-21
BR112017001287A2 (pt) 2018-01-30
HRP20230223T1 (hr) 2023-04-14
ZA201701241B (en) 2022-05-25
CA2955914C (en) 2022-09-06
JP6534439B2 (ja) 2019-06-26
EP3173382A4 (en) 2018-03-21
EP3173382A1 (en) 2017-05-31
TW201618796A (zh) 2016-06-01
MX2017000927A (es) 2017-05-01
LT3173382T (lt) 2023-03-27
CA2955914A1 (en) 2016-01-28
SMT202300086T1 (it) 2023-05-12
MX383705B (es) 2025-03-14
SI3173382T1 (sl) 2023-04-28
AU2014401750A1 (en) 2017-02-09
JP2017523170A (ja) 2017-08-17
US10376540B2 (en) 2019-08-13
RU2679623C2 (ru) 2019-02-12
HUE061726T2 (hu) 2023-08-28
PL3173382T3 (pl) 2023-05-08
RU2017105257A3 (es) 2018-08-21

Similar Documents

Publication Publication Date Title
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
WO2014194254A8 (en) Treatment of cancers using pi3 kinase isoform modulators
EP4610279A3 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX389228B (es) Composiciones para tratar el cabello.
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
EP4233910A3 (en) Methods of treatment of cholestatic diseases
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
MX2018002344A (es) Metodo para tratar el cancer.
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
WO2018125800A3 (en) Metalloenzyme inhibitor compounds
EP4286013A3 (en) Lrrc33 inhibitors and use thereof
WO2015143447A3 (en) Methods for treating neurological disorders
HK1254954A1 (zh) Lpt-723和免疫检查点抑制剂组合物及其治疗方法
WO2017019721A3 (en) Combinations of ezh2 inhibitors with further agents for use in the treatment of cancer
WO2016012632A9 (es) Sales de tungsteno (vi) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida
WO2015169811A3 (en) Anti-cxc chemokine receptor-2 binding molecules and uses thereof
WO2015138761A3 (en) Methods for treating peripheral nerve damage
WO2015156674A3 (en) Method for treating cancer
WO2016135456A3 (en) A gm-csf negative modulator for use in treating, preventing or ameliorating aortopathy
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
WO2015134603A3 (en) Methods for treating cancer
EP4470624A3 (en) Methods of administering anti-fibrotic therapy
HK1232071A1 (zh) 使用mtan抑制剂治疗h.pylori感染
EP4335508A3 (en) (+)-azasetron for use in the treatment of ear disorders
WO2015191636A3 (en) Xanthine oxidase inhibitors and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14898173

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017502966

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15327292

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2955914

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 122022022738

Country of ref document: BR

Ref document number: MX/A/2017/000927

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 250212

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017001287

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2014401750

Country of ref document: AU

Date of ref document: 20140721

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20177004653

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014898173

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014898173

Country of ref document: EP

Ref document number: 1020177004653

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2017105257

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112017001287

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170120